BioSpace News Archive

$98.7M financing, development fees and commercial milestone commitments accelerate the development and commercialization of One Drop’s digital health platform and data-driven predictive capabilities across multiple therapeutic areas

NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, announced that the U.S. Food and Drug Administration has cleared its investigational new drug application for the combination of its lead drug candidate, NT-I7, a novel long-acting human interleukin-7, and Kymriah®, a CD19 CAR T-cell therapy, for the treatment of patients with relapsed/refractory large B cell lymphoma.

Prelude Therapeutics, a privately-held, clinical-stage precision oncology company, announced that it has completed a $50 million Series C financing round led by Prelude’s two existing institutional investors, including OrbiMed Advisors LLC, and a new investor, Fidelity Management & Research Company LLC.

IV rigosertib did not meet primary endpoint of significantly improved survival versus best supportive care in higher-risk myelodysplastic syndromes (HR-MDS) Onconova will focus on promising pipeline opportunities including with its CDK4/6 + ARK5 inhibitor ON 123300 Onconova to host conference call today at 8:30 a.m. ET NEWTOWN, Pa., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) a biopharmaceutical company focused on discovering and developing novel produ

Inovalon (Nasdaq: INOV), a leading provider of cloud-based platforms empowering data-driven healthcare, today announced that Keith Dunleavy, M.D., chief executive officer and chairman of the board of Inovalon, and Jonathan R. Boldt, chief financial officer of Inovalon, will participate in a virtual fireside chat at KeyBanc Capital Markets’ Future of Technology Series

The global iontophoresis units market is estimated to be influenced by the rising incidences of various diseases like rheumatoid arthritis and hyperhidrosis.

Hutchison China MediTech Limited announces that new and updated analyses on the studies of surufatinib and fruquintinib will be presented at the upcoming European Society for Medical Oncology Virtual Congress 2020, taking place on September 17-21, 2020.

In recent years, considerable progress has been made in life science research. As an interdisciplinary field, bioinformatics services combines computer science, statistics and life sciences together in the form of algorithms.

Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators, a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce that Karn Manhas, Founder and CEO of Terramera and agtech industry pioneer, has joined Qu Biologics’ Board of Directors.

International Phase 2/3 trial in countries with high rates of coronavirus infection planned to start late 2020, pending initial Phase 1 outcome